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Abstract
BACKGROUND—There is limited evidence from nationally representative samples about 
changes in prescription drug use for financial reasons among cancer survivors in the United States.
METHODS—The 2011 to 2014 National Health Interview Survey was used to identify adults 
who reported ever having been told they had cancer (cancer survivors; n = 8931) and individuals 
without a cancer history (n = 126,287). Measures of changes in prescription drug use for financial 
reasons included: 1) skipping medication doses, 2) taking less medicine, 3) delaying filling a 
prescription, 4) asking a doctor for lower cost medication, 5) buying prescription drugs from 
another country, and 6) using alternative therapies. Multivariable logistic regression analyses were 
controlled for demographic characteristics, number of comorbid conditions, interactions between 
cancer history and number of comorbid conditions, and health insurance coverage. Main analyses 
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were stratified by age (nonelderly, ages 18–64 years; elderly, ages ≥65 years) and time since 
diagnosis (recently diagnosed, <2 years; previously diagnosed, ≥2 years).
RESULTS—Among nonelderly individuals, both recently diagnosed (31.6%) and previously 
diagnosed (27.9%) cancer survivors were more likely to report any change in prescription drug use 
for financial reasons than those without a cancer history (21.4%), with the excess percentage 
changes for individual measures ranging from 3.5% to 9.9% among previously diagnosed 
survivors and from 2.6% to 2.7% among recently diagnosed survivors (P < .01). Elderly cancer 
survivors and those without a cancer history had comparable rates of changes in prescription drug 
use for financial reasons.
CONCLUSIONS—Nonelderly cancer survivors are particularly vulnerable to changes in 
prescription drug use for financial reasons, suggesting that targeted efforts are needed.
Keywords
cancer survivors; comorbid conditions; financial burden; high-deductible plan; prescription drugs
INTRODUCTION
The rising cost of cancer drugs imposes a significant financial burden on patients with 
cancer and their families.1,2 The direct medical cost of a new cancer medication per patient 
can routinely exceed $100,000 annually.2,3 Because of rising deductibles, copayments, 
coinsurance, and tiered drug formularies, an increasing portion of the cost of cancer drugs is 
shifted to the patient as out-of-pocket (OOP) costs.4,5 Previous studies demonstrated that 
cancer survivors faced significantly higher OOP costs than individuals without a cancer 
history.6–8 The financial burden caused by the high OOP costs for cancer drugs may further 
impair cancer survivors’ overall well being, adversely affect treatment choices and health 
outcomes, and result in higher medical expenditures in the long run.9–13 Moreover, the 
increasing number of expensive, patient-administrated, oral antineoplastic agents may 
increase the likelihood that patients with cancer may delay, skip, or even forgo their 
prescription medications for financial reasons.13–16
A cancer diagnosis is associated with reduced adherence to recommended prescription drugs 
for other comorbid conditions, such as diabetes and cardiovascular disease, although, in 
some studies, it was unknown whether this was for financial reasons.17–19 Previous studies 
demonstrating that patients with cancer make changes in prescription drug use to defray 
OOP costs are limited to small sample sizes, specific cancer sites, single-institutional 
experience, or trials without a noncancer control group.11,20–22 In the current study, we used 
nationally representative data to compare the changes in prescription drug use for financial 
reasons between cancer survivors and individuals without a cancer history. Because the 
intensity and aggressiveness of cancer-related treatments and associated costs are likely to be 
greater in nonelderly than in elderly patients and in those diagnosed in the most recent time 
period than in the past,23–25 we stratified the analyses by age group and time since 
diagnosis. Moreover, we examined whether high private health insurance deductibles were 
associated with changes in prescription drug use for financial reasons among nonelderly 
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cancer survivors. We also examined whether the pattern of changes in prescription drug use 
varies according to the number of comorbid conditions among cancer survivors.
MATERIALS AND METHODS
Data Sources
The National Health Interview Survey (NHIS) from 2011 through 2014 was used to identify 
cancer survivors and individuals without a cancer history. The NHIS is a cross-sectional 
household interview survey conducted annually by the Centers for Disease Control and 
Prevention’s National Center for Health Statistics. It is a nationally representative survey of 
the civilian, noninstitutionalized population of the United States. The survey collects 
information on health status, access to and use of health care services, and comorbid 
conditions. The annual NHIS response rate ranged from 73.8% to 82% of eligible 
households during our study period.26
Individual-Level Characteristics and Analytic Sample
In the NHIS, cancer history is self-reported. We defined cancer survivors as those who 
reported ever having been told by a physician or other health professional that they had 
cancer or a malignancy of any kind. Cancer survivors who reported nonmelanoma skin 
cancer or skin cancer with unknown type were excluded.27,28 Individual-level demographic 
and clinical characteristics included, age at the time of the survey (nonelderly: ages 18–49 or 
50–64 years; elderly: ages 65–74 or ≥75 years), sex, race/ethnicity (non-Hispanic white, 
non-Hispanic black, Hispanic, or other), educational attainment (≤high school graduate or 
≥some college), marital status (married or not married), geographic region (Northeast, 
Midwest, South, or West), health insurance coverage, and number of comorbid conditions 
(0, 1, 2, or ≥3). The health insurance coverage variable was defined differently for the 2 age 
groups (nonelderly: any private, other, or uninsured; elderly: Medicare with any private or 
other). Comorbid conditions included: arthritis, asthma, diabetes, emphysema, coronary 
heart disease, hypertension, stroke, angina pectoris, and heart attack.
Time since diagnosis was calculated using age at cancer diagnosis and age at the time of the 
survey. We used 2 years as the cutoff point for categorizing those who were recently 
diagnosed and previously diagnosed to be consistent with previous studies.7,29 In the NHIS, 
private health insurance with an annual deductible >$1200 per individual or $2400 per 
family was categorized as a high-deductible plan.26 An indicator for high insurance 
deductible status was created among nonelderly cancer survivors who had any private health 
insurance coverage during the survey year. The final sample was stratified by age group 
(nonelderly population, ages 18–64 years; elderly population, ages ≥65 years) and time since 
diagnosis (recently diagnosed, <2 years; previously diagnosed, ≥2 years), including recently 
diagnosed (nonelderly, n = 686; elderly, n = 720) and previously diagnosed (nonelderly, n = 
3295; elderly, n = 4230) cancer survivors and individuals without a cancer history 
(nonelderly, n = 76,096; elderly, n =16,989).
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Measures of Changes in Prescription Drug Use for Financial Reasons
The NHIS included 6 measures of changes in prescription drug use for financial reasons. 
These are general questions about all prescriptions drugs and thus are not cancer specific. 
Respondents were asked the following questions: “During the past 12 months, were any of 
the following true for you: 1) you skipped medication doses to save money, 2) you took less 
medicine to save money, 3) you delayed filling a prescription to save money, 4) you asked 
your doctor for a lower cost medication to save money, 5) you bought prescription drugs 
from another country to save money, 6) you used alternative therapies to save money.” A 
summary measure (yes/no) of any of the 6 measures and a categorical count of changes in 
prescription drug use for financial reasons (scored as 0, 1, or ≥2) also were also created.
Statistical Methods
We compared the distributions of individual-level characteristics between cancer survivors 
and those without a cancer history. We used multivariable logistic regression models for 
each of the 6 measures and the summary measure to estimate the changes in prescription 
drug use for financial reasons for both cancer survivors and individuals without a cancer 
history. Among nonelderly cancer survivors with private health insurance, we used 
multivariable logistic regressions to compare the patterns of changes in prescription drug use 
between high-deductible plans and low-deductible plans. We did not examine this 
association among the elderly cancer survivors because of their nearly universal eligibility 
for insurance through Medicare. Among all cancer survivors, multivariable ordered logistic 
regression was used to investigate associations between the number of comorbid conditions 
and changes in prescription drug use for financial reasons. Sensitivity analyses were 
conducted to examine the robustness of our findings by evaluating various summary 
measures based on a different reduced set of questions about changes in prescription drug 
use.
All multivariable regressions adjusted for survey year, age, race/ethnicity, sex, educational 
attainment, marital status, geographic region, health insurance coverage, the number of 
comorbid conditions, and interactions between cancer history and the number of comorbid 
conditions. The NHIS annual sampling weights were adjusted to reflect pooling data across 
multiple years and were used in all analyses to provide nationally representative estimates.30 
All adjusted estimates of changes in prescription drug use for financial reasons are presented 
as predictive margins.31 All analytic files were created using SAS version 9.3. Multivariable 
logistic and ordered logistic regressions were performed using STATA 13.1. Statistical 
comparisons were 2-sided, and significance was defined as P < .05.
RESULTS
Distribution of Individual-Level Characteristics and Unadjusted Changes in Prescription 
Drug Use for Financial Reasons
Compared with individuals who had no history of cancer, cancer survivors were more likely 
to be older, non-Hispanic white, married (nonelderly population only), and privately insured 
and to have more comorbid conditions (Table 1). Nonelderly cancer survivors were more 
likely to be women, whereas elderly cancer survivors were more likely to be men compared 
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with individuals who had no history of cancer. Among privately insured non-elderly cancer 
survivors, 41% of those who were recently diagnosed and 64% of those who were 
previously diagnosed enrolled in high-deductible plans. We also observed that both recently 
diagnosed and previously diagnosed nonelderly cancer survivors were more likely to report 
changes in prescription drug use for financial reasons than individuals without a history of 
cancer.
Adjusted Changes in Prescription Drug Use Between Cancer Survivors and Individuals 
Without a Cancer History
In the adjusted analyses, we observed that nonelderly cancer survivors were more likely to 
report changes in prescription drug use for financial reasons than nonelderly individuals 
without a cancer history (see Fig. 1 for total percentage changes and Table 2 for excess 
percentage changes). For the summary measure, 31.6% of recently diagnosed and 27.9% of 
previously diagnosed cancer survivors reported any change in prescription drug use for 
financial reasons, compared with 21.4% of individuals without a cancer history. The excess 
changes in prescription drug use for financial reasons associated with cancer were 10.2% 
(95% confidence interval [CI], 5.6%–14.8%) and 6.6% (95% CI, 4.4%–8.7%; all P < .05) 
for recently and previously diagnosed cancer survivors, respectively.
For individual measures among the nonelderly population, we observed that, compared with 
the control group: 1) 8.8% of previously diagnosed cancer survivors reported skipping 
medication doses (excess change, 2.7%; 95% CI, 1.4%–3.9%); 2) 9.9% of recently 
diagnosed and 9.3% of previously diagnosed cancer survivors reported taking less medicine 
(excess changes, 3.5% [95% CI, 0.3%–6.6%] and 2.8% [95% CI, 1.6%–4.1%], 
respectively); 3) 13.2% of recently diagnosed and 11.7% of previously diagnosed cancer 
survivors reported delaying filing a prescription (excess changes, 5.2% [95% CI, 1.4%–
9.1%] and 3.7% [95% CI, 2.3%–5.1%], respectively); 4) 25.8% of recently diagnosed and 
21.9% of previously diagnosed cancer survivors reported asking for lower cost medication 
(excess changes, 9.9% [95% CI, 5.6%–14.2%] and 6% [95% CI, 4.1%–7.9%], respectively); 
and 5) 7.4% of previously diagnosed cancer survivors reported using alternative therapies 
(excess change, 2.6%; 95% CI, 1.3%–3.8%; all P < .05).
Among the elderly population, we observed that, compared with the control group: 1) 22.6% 
of recently diagnosed cancer survivors reported asking for lower cost medication (excess 
change, 5% [95% CI, 1%–9.1%]; 2) on average, approximately 4% of previously diagnosed 
cancer survivors reported skipping medication doses, taking less medicine, and delaying 
filling a prescription (excess change, <1%) compared with individuals without a cancer 
history (all P < .05).
When the analyses were stratified by the number of comorbid conditions and compared with 
the control group (Supporting Table 1; see online supporting information), we observed that 
nonelderly cancer survivors were more likely to report changes in prescription drug use for 
financial reasons when the number of comorbid conditions was ≤1 for recently diagnosed 
patients and ≤2 for previously diagnosed patients (all P < .05). Elderly cancer survivors and 
those without a cancer history had comparable rates of changes in prescription drug use for 
financial reasons when stratified by the number of comorbid conditions.
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Insurance Deductible Status and Adjusted Changes in Prescription Drug Use for Financial 
Reasons Among Nonelderly Cancer Survivors
Among privately insured nonelderly cancer survivors, 806 were enrolled in high-deductible 
plans, and 1399 enrolled in low-deductible plans (Fig. 2). Compared with those enrolled in 
low-deductible plans (22.5%), nonelderly cancer survivors enrolled in high-deductible plans 
(32.2%) were more likely to ask their doctor for lower cost medication (odds ratio, 1.71; 
95% CI, 1.32–2.22) (Supporting Table 2; see online supporting information).
Adjusted Changes in Prescription Drug Use by Number of Comorbid Conditions Among 
Cancer Survivors
We observed that, as the number of comorbid conditions increased from 0 to ≥ 3 (Fig. 3): 1) 
the adjusted percentages of nonelderly cancer survivors increased from 24% to 51.2% for 
reporting any change and from 11.1% to 29.7% for reporting 2 or more changes in 
prescription drug use (all P < .001), respectively; 2) the adjusted percentages of elderly 
cancer survivors increased from 11.8% to 28.3% for reporting any change and from 2.6% to 
7.5% for reporting 2 or more changes in prescription drug use (all P < .001), respectively. 
Time since diagnosis was not associated with the number of changes in prescription drug use 
that cancer survivors reported for financial reasons (Supporting Table 3; see online 
supporting information).
Sensitivity Analysis
Our findings of the summary measure were robust to various definitions that included 
different measures between cancer survivors and those without a cancer history (Supporting 
Table 4; see online supporting information).
DISCUSSION
Our study used a nationally representative sample to estimate patterns of changes in 
prescription drug use for financial reasons in both the nonelderly and elderly population of 
cancer survivors in the United States. We observed that both recently and previously 
diagnosed cancer survivors in the United States are more likely to alter their prescription 
drug use for financial reasons compared with individuals who do not have a history of 
cancer. This is particularly true in the nonelderly population. Moreover, nonelderly cancer 
survivors with high-deductible plans are more likely to ask for lower cost medication than 
those with low-deductible plans.
Nonelderly cancer survivors are particularly vulnerable to the risk of changing their 
prescription drug use for financial reasons, which may be explained in part by the complex 
relationship between employment and insurance coverage. A cancer diagnosis can result in 
barriers to working, productivity loss at work, reduced income, and employment disability.
7,8,32–34
 The loss of employment-based insurance coverage increases the likelihood of 
delaying and missing care because of cost.35 Cancer survivors have been reported to have 
difficulties living within their household income, accrued debt, sold or refinanced their 
home, borrowed money from friends or family, or experienced a decline ≥20% in annual 
income because of treatment-related expenses.9,36 Our findings are consistent with the 
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literature indicating that younger age is associated with increased risks of cancer-related 
financial problems and higher rates of personal bankruptcy because of medical bills.9,29,32
Although elderly cancer survivors are likely to take more prescription drugs than elderly 
individuals without a history of cancer and may forgo expensive cancer drugs for financial 
reasons, we did not observe systematic differences in the probabilities of reporting changes 
in prescription drug use for financial reasons between them. This is likely because of the 
near universal enrollment in Medicare, including prescription drug coverage for many, 
which may reduce the impact of medication cost on drug use.23 Moreover, the measures of 
changes in prescription drug use include both cancer drugs and prescription drugs for other 
comorbid conditions. More than one-half of elderly individuals without a history of cancer 
had 2 or more comorbid conditions, which may also require prescription drugs. Although 
nonelderly and elderly populations are quite different in health status and financial situation, 
our results suggest that establishing programs that expand equitable access to care and 
prescription coverage in the nonelderly population can attenuate the financial burden of 
prescription drugs.
In the current study, we observed that the number of comorbid conditions was associated 
with changes in prescription drug use for financial reasons among cancer survivors. Others 
have reported that a new cancer diagnosis was associated with nonadherence to prescription 
drugs for diabetes and cardiovascular disease,17–19 which can have adverse consequences for 
the treatment of these conditions and may increase the risk of competing illnesses. Cancer is 
a life-threatening disease and may shift the focus of patients and providers from other 
comorbid conditions to cancer-related treatments.37 In addition, the discontinuation of 
recommended prescription drugs for other co-morbid conditions may result from a poor 
cancer prognosis, in which the risk of dying from cancer exceeds the risk of dying from 
other comorbid conditions.19,38
Our finding of an association between health insurance deductible status and asking 
physicians for lower cost medication among privately insured nonelderly cancer survivors is 
consistent with the research literature indicating that high OOP costs are associated with 
medication nonadherence.13,21,39–42 Future studies should monitor the changes in 
prescription drug use among cancer survivors, because several provisions of the Affordable 
Care Act (ACA) may play an important role in providing insurance coverage and reducing 
OOP costs.43 Under the ACA, nonelderly cancer survivors will not be precluded from 
coverage because of preexisting conditions and will not lose coverage because of a cancer 
diagnosis. Elderly cancer survivors will benefit from the elimination of the coverage gap in 
Medicare Part D. Affordable health insurance plans through the Health Insurance 
Marketplace and tax credits toward reductions in OOP costs will also help cancer survivors 
reduce financial burden. Additional coverage through Medicaid expansion in certain states 
will also help low-income families lower the financial burden associated with cancer and its 
treatments. However, the extent to which the ACA can improve medication adherence 
among cancer survivors and whether total health care costs can be reduced because of 
improved treatment outcomes remain to be examined.44,45
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Although we do not have information about whether these measures of changes in 
prescription drug use were specifically for cancer, our results from the summary measure 
were robust for the majority of cancer survivors in our sample when stratified according to 
the number of co-morbid conditions. Therefore, our findings have implications for both 
oncologists and primary care physicians. The American Society of Clinical Oncology has 
identified patient-oncologist communication about cost as an important component of high-
quality cancer care.46 However, the majority of patients with cancer do not discuss costs 
with their providers despite their common concerns about the financial burden.47,48 Medical 
oncologists also need guidance about how to discuss costs with their patients, particularly 
when incremental costs are substantial but the marginal benefit is very small.46,49–51 
Moreover, the increasing availability of expensive oral regimens may also require 
oncologists and patients to discuss the financial burden when making treatment decisions.
3,52–56
 Primary care physicians may want to consider the overall financial burden of 
prescription drugs among cancer survivors when coordinating care with oncologists, 
managing other comorbid conditions, and providing follow-up care to patients with cancer.
57,58
Our study has several limitations. The cancer history was self-reported. However, previous 
studies indicated that medical records and self-reported cancer history are highly consistent.
59,60
 Time since diagnosis was measured by the difference between age at the time of the 
survey and age at cancer diagnosis,7,28,61 which may have been subject to measurement 
error. Moreover, we did not have information on health insurance premiums, copayments, or 
coinsurance. Despite these limitations, our study used a nationally representative sample of 
adult cancer survivors, a comparison group without a history of cancer in both nonelderly 
and elderly populations, and detailed measures of health insurance stratified by age group. 
Our study provides a comprehensive analysis on the patterns of changes in prescription drug 
use at the national level and can be used to improve the quality of care among cancer 
survivors.
Conclusions
Compared with individuals without a cancer history, US cancer survivors face greater risks 
of changing their prescription drug use for financial reasons, particularly those aged <65 
years. The patterns of changes in prescription drug use among cancer survivors vary by the 
number of comorbid conditions. Health care policies that help cancer survivors address the 
financial burden of prescription drugs should target those who have multiple comorbid 
conditions and high-deductible health plans.
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Figure 1. 
Individual measures and summary measures of changes in prescription drug use for financial 
reasons are illustrated among cancer survivors and individuals without a cancer history 
(National Health Interview Survey, 2011–2014). All analyses were stratified by age 
(nonelderly vs elderly) and time since diagnosis (recently diagnosed vs previously 
diagnosed). Multivariable logistic regressions controlled for survey year, age, race/ethnicity, 
sex, educational attainment, marital status, number of comorbid conditions, health insurance 
coverage, and geographic region. Blue bars represent individuals without a cancer history; 
red bars, recently diagnosed cancer survivors; green bars, previously diagnosed cancer 
survivors.
Zheng et al. Page 12
Cancer. Author manuscript; available in PMC 2018 August 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
Patterns of changes in prescription drug use for financial reasons are illustrated among 
nonelderly cancer survivors who were enrolled in high-deductible plans versus low-
deductible plans (multivariable adjusted; National Health Interview Survey, 2011–2014).
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Figure 3. 
Patterns of changes in prescription drug use for financial reasons are illustrated by the 
number of comorbid conditions among cancer survivors only (multivariable, ordered logistic 
regression stratified by age [18–64 vs ≥ 65 years]; National Health Interview Survey, 2011–
2014). Blue areas represent the percentages of cancer survivors that had no change in 
prescription drug use; red areas, the percentages that had exactly 1 change in prescription 
drug use; green areas, the percentages that had at least 2 changes in prescription drug use.
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TABLE 2
Excess Adjusted Changes in Prescription Drug Use for Financial Reasons Among Cancer Survivors Compared 
With Individuals Without a Cancer History: Results From Multivariable Logistic Regression and Stratified by 
Age (18–64 vs ≥65 Years), 2011–2014 National Health Interview Studya
Changes in Prescription Drug Use Measures
Cancer Survivors
Recently Diagnosed: <2 Years Previously Diagnosed: ≥2 Years
Excess Percentage (95% CI) Pb Excess Percentage (95% CI) Pb
Ages 18–64 y n = 715 n = 3,519
 Summary measurec 10.2 (5.6, 14.8) < .001 6.6 (4.4, 8.7) < .001
 1. Skipped medication dosesd 1.8 (−0.5, 4.0) .121 2.7 (1.4, 3.9) < .001
 2. Took less medicine 3.5 (0.3, 6.6) .032 2.8 (1.6, 4.1) < .001
 3. Delayed filling a prescription 5.2 (1.4, 9.1) .007 3.7 (2.3, 5.1) < .001
 4. Asked doctor for lower cost medication 9.9 (5.6, 14.2) < .001 6.0 (4.1, 7.9) < .001
 5. Bought prescription drugs from another country 0.9 (−1.2, 3.0) .411 0.7 (−0.3, 1.7) .186
 6. Used alternative therapies 2.3 (−0.5, 5.2) .113 2.6 (1.3, 3.8) < .001
Aged ≥65 y n = 781 n = 4,546
 Summary measurec 4.5 (0.2, 8.8) .041 1.5 (−0.3, 3.2) .099
 1. Skipped medication doses −0.3 (−1.5, 0.9) .629 0.9 (0.1, 1.6) .017
 2. Took less medicine −0.3 (−1.5, 0.9) .605 0.7 (0.1, 1.4) .037
 3. Delayed filling a prescription 0.0 (−1.5, 1.5) .999 0.9 (0.1, 1.7) .035
 4. Asked doctor for lower cost medication 5.0 (1.0, 9.1) .016 1.5 (−0.2, 3.1) .079
 5. Bought prescription drugs from another country 0.8 (−0.5, 2.2) .241 0.4 (−0.2, 1.0) .214
 6. Used alternative therapies −0.6 (−1.5, 0.3) .187 0.6 (−1.1, −0.1) .012
Abbreviations: CI, confidence interval; OR, odds ratio.
aAll statistical tests were 2-sided, and all P values were derived from multivariable logistic regressions. All logistic regression analyses were 
controlled for survey year, age, sex, race/ethnicity, education, marital status, number of comorbid conditions, interactions between cancer history 
and number of comorbid conditions, health insurance status, and geographic region (Northeast, Midwest, South, and West).
bP values reflect the statistical significance level of the changes in prescription drug use among cancer survivors versus individuals without a cancer 
history using multivariable logistic regression analysis.
cAll questions about changes in prescription drug use were asked for the last 12 months at the time of the survey. It was determined that the 
respondent was trying to save money if any of the items (skipped medication doses, took less medicine, delayed filing a prescription, asked doctor 
for lower cost medication, bought prescription drugs from another country, or used alternative therapies) were reported.
d
The survey question asks, “During the past 12 months, were any of the following true for you? . . .You skipped medication doses to save money.”
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